biote Corp.

Biote Corp., trading under the ticker BTMD, is a hormone health company that operates in the healthcare sector, focusing on bioidentical hormone replacement therapy training and practice support for medical providers. The company went public through a de-SPAC transaction with Haymaker Acquisition Corp. III, a blank-check company sponsored by Haymaker Partners, whose principals include Andrew Taub and Steven Flyer. The SPAC completed its IPO in 2021, and this December 2021 Form 8-K filing with accession number 0001193125-21-354781 reflects activity during the active phase of the business combination process. The merger was subsequently completed in 2022, bringing Biote into the public markets as BTMD. Sign up for full data, filings, and analytics on SpacDesk at spacdesk.com.